SEMA3A and infection: We constructed AAV9‐ENT vectors (based on adeno‐associated virus 9 (AAV9) serotype modification and enhanced the infection efficiency of vascular endothelial cells) carrying Sema3A‐shRNA under the ICAM2 promoter (Figure8A); we then, we delivered these AAV9‐ENT vectors through the tail veins of mice (Figure 8B).